Roche Holding AG
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 287
- Registration Number
- NCT01903993
- Locations
- πΊπΈ
Kaiser Permanente - Vallejo, Vallejo, California, United States
πΊπΈNew York Oncology Hematology, P.C., Albany, New York, United States
πΊπΈWenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 283
- Registration Number
- NCT01903954
OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis
- Conditions
- Anemia
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 437
- Registration Number
- NCT01902628
- Locations
- π¬π·
Laiko General Hospital; Nephrology Div., Athens, Greece
π¬π·General Hospital Of Athens G.Gennimatas; Nephrology, Athens, Greece
π¬π·Uni Hospital of Alexandroupoli; Nephrology Dept., Alexandroupolis, Greece
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT01902615
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 61
- Registration Number
- NCT01901172
A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01901159
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01898598
- Locations
- πΊπΈ
Loma Linda University Medical Center, Loma Linda, California, United States
πΊπΈMayo Clinic, Scottsdale, Arizona, United States
πΊπΈUniversity of Minnesota, Minneapolis, Minnesota, United States
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT01898585
- Locations
- πΏπ¦
Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town, South Africa
πΏπ¦Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa
πΏπ¦Mary Potter Oncology Centre, Groenkloof, South Africa
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01897038
A Study of RO6799477 in Healthy Volunteers
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT01893437